Figure 6.

Implications of IL6/JAK2 signalling in CD90+ liver cancer cells. A, Alteration of IL6/JAK2 signalling components in CD90+ 97L and Huh7 liver cancer cells treated with SHH. GAPDH was used as the internal standard. B, Proliferation rates of CD90+ 97L liver cancer cells treated with a combination of SHH and AZD1480 using the MTS assay. C, Sphere formation capacity of CD90+ liver cancer cells treated with SHH and AZD1480. D, Migration capacities of CD90+ liver cancer cells treated with SHH and AZD1480 by the transwell assay. E, Proliferation rates of CD90+97L liver cancer cells treated with a combination of SHH and IL6 neutralizing antibody using the MTS assay. F, Sphere formation capacity of CD90+ liver cancer cells treated with SHH and IL6 neutralizing antibody. G, Migration capacities of CD90+ liver cancer cells treated with SHH and IL6 neutralizing antibody by the transwell assay; SHH: Sonic Hedgehog; IL6: interleukin‐6; p‐JAK2: phosphorylated Janus kinase 2; p‐STAT3: phosphorylated signal transducer and activator of transcription 3; SOX2: Sex Determining Region Y‐Box 2; GAPDH: glyceraldehyde‐3‐phosphate dehydrogenase